NTRK1 and cancer: Aberrant activation of this pathway, commonly resulting from mutations in PIK3CA, loss of PTEN tumor suppressor function, or receptor tyrosine kinase overexpression, confers growth advantages and therapeutic resistance to cancer cells [51].